Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The European Respiratory Journal|February 1, 1996
Role of cyclic AMP in the modulation of IgE production by the beta 2-adrenoceptor agonist, fenoterolO Coqueret, D Demarquay, V Lagente
Annals of the New York Academy of Sciences|February 24, 2001
Homocamptothecins: E-ring modified CPT analoguesO Lavergne, D Demarquay, P G Kasprzyk, et al.
Experimental Cell Research|October 1, 1992
Stimulation by GH of IGF1 proforms synthesized by rabbit chondrocytes cultured with bFGF in serum-free mediumD Demarquay, M F Dumontier, J Bourguignon, et al.
Hormone Research|January 1, 1990
In vitro insulin-like growth factor I interaction with cartilage cells derived from postnatal animalsD Demarquay, M F Dumontier, L Tsagris, et al.
Biochemistry|November 26, 1999
Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaksC Bailly, A Lansiaux, L Dassonneville, et al.
Anti-Cancer Drug Design|January 5, 2002
A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38C Bailly, W Laine, B Baldeyrou, et al.
Cancer Research|June 26, 1999
Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor propertiesL Lesueur-Ginot, D Demarquay, R Kiss, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 1999
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase IIO Lavergne, J Harnett, A Rolland, et al.
Molecular Pharmacology|August 15, 2001
Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cellsA Lansiaux, M Facompré, N Wattez, et al.
Anti-Cancer Drugs|March 29, 2001
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poisonD Demarquay, M Huchet, H Coulomb, et al.
Pageof 2